Literature DB >> 21360302

Protective effects of human umbilical cord blood stem cell intravitreal transplantation against optic nerve injury in rats.

Tantai Zhao1, Yunqin Li, Luosheng Tang, Yuehua Li, Fang Fan, Bing Jiang.   

Abstract

BACKGROUND: The majority of studies addressing traumatic optic neuropathy (TON) have focused on drugs, proteins, cytokines, and various surgical techniques. A recent study reported that transplantation of human umbilical cord blood stem cells (hUCBSCs) achieved therapeutic effects on TON, but the exact effects on optic nerve injury are still unknown, and the mechanisms underlying nerve protection remain poorly understood.
METHODS: A total of 135 healthy Sprague-Dawley adult rats were randomly assigned to three groups: sham-surgery, model and transplantation, with 45 rats in each group. TON was induced in the model and transplantation groups via optic nerve crush injury. The crush injury was not performed in the sham-surgery group. Seven days after the injury, 10(6) hUCBSCs were injected into the rat vitreous cavity of transplantation group, and an equal volume of physiological saline was administered to the model and sham-surgery groups. Pathological observation of rat retina tissues was performed by hematoxylin-eosin (H&E) staining at days 3, 7, 14, 21 and 28 post-surgery. The number of retinal ganglion cells (RGCs) and mRNA expression levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) were assessed by the Fluorogold (FG) retrograde labeling and reverse transcriptase-polymerase chain reaction (RT-PCR) methods, respectively.
RESULTS: The number of labeled RGCs and the expression of BDNF and GDNF mRNA obviously increased, and pathological injury was significantly ameliorated in the transplantation group compared to the model group (P < 0.05).
CONCLUSIONS: Via intravitreal transplantation, the hUCBSCs resulted in a significant increase in the survival of the RGCs, and improved pathological changes in the rat retina, following TON. The protective mechanism is correlated with the continuous secretion of BDNF and GDNF in vivo of retina in optic nerve injury rats by the transplanted hUCBSCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360302     DOI: 10.1007/s00417-011-1635-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  31 in total

1.  AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells.

Authors:  S G Leaver; Q Cui; G W Plant; A Arulpragasam; S Hisheh; J Verhaagen; A R Harvey
Journal:  Gene Ther       Date:  2006-05-18       Impact factor: 5.250

2.  Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study.

Authors:  Guillermo Parrilla-Reverter; Marta Agudo; Paloma Sobrado-Calvo; Manuel Salinas-Navarro; María P Villegas-Pérez; Manuel Vidal-Sanz
Journal:  Exp Eye Res       Date:  2009-03-04       Impact factor: 3.467

Review 3.  Traumatic optic neuropathy.

Authors:  K D Steinsapir
Journal:  Curr Opin Ophthalmol       Date:  1999-10       Impact factor: 3.761

Review 4.  [Umbilical cord blood as a source of stem cells].

Authors:  Ines Bojanić; Branka Golubić Cepulić
Journal:  Acta Med Croatica       Date:  2006-06

Review 5.  Adult stem cell therapy in stroke.

Authors:  Sebastian Haas; Norbert Weidner; Jürgen Winkler
Journal:  Curr Opin Neurol       Date:  2005-02       Impact factor: 5.710

6.  Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party.

Authors:  A Bacigalupo; J Hows; E C Gordon-Smith; E Gluckman; M T Van Lint; M Congiu; D C James; A J Barrett; J Gmur; M M De Planque
Journal:  Bone Marrow Transplant       Date:  1988-11       Impact factor: 5.483

Review 7.  Optic nerve and neuroprotection strategies.

Authors:  N N Osborne; G Chidlow; C J Layton; J P M Wood; R J Casson; J Melena
Journal:  Eye (Lond)       Date:  2004-11       Impact factor: 3.775

8.  Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time.

Authors:  Brian A van Adel; Corinne Kostic; Nicole Déglon; Alexander K Ball; Yvan Arsenijevic
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

Review 9.  [Traumatic optic neuropathy--the present state].

Authors:  H Wilhelm
Journal:  Klin Monbl Augenheilkd       Date:  2004-08       Impact factor: 0.700

10.  [Endoscopic decompression of the optic nerve in patients with post-traumatic vision impairment].

Authors:  Andrzej Sieśkiewicz; Tomasz Łysoń; Zenon Mariak; Marek Rogowski
Journal:  Klin Oczna       Date:  2008
View more
  21 in total

1.  Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome.

Authors:  Thomas V Johnson; Nicholas W DeKorver; Victoria A Levasseur; Andrew Osborne; Alessia Tassoni; Barbara Lorber; Janosch P Heller; Rafael Villasmil; Natalie D Bull; Keith R Martin; Stanislav I Tomarev
Journal:  Brain       Date:  2013-10-30       Impact factor: 13.501

2.  Neuroprotective effects of BDNF and GDNF in intravitreally transplanted mesenchymal stem cells after optic nerve crush in mice.

Authors:  Zong-Li Hu; Ni Li; Xin Wei; Li Tang; Ting-Hua Wang; Xiao-Ming Chen
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

Review 3.  Progress of mesenchymal stem cell therapy for neural and retinal diseases.

Authors:  Tsz Kin Ng; Veronica R Fortino; Daniel Pelaez; Herman S Cheung
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

4.  A novel animal model of partial optic nerve transection established using an optic nerve quantitative amputator.

Authors:  Xu Wang; Ying Li; Yan He; Hong-Sheng Liang; En-Zhong Liu
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

5.  Intraocular pressure reduction and neuroprotection conferred by bone marrow-derived mesenchymal stem cells in an animal model of glaucoma.

Authors:  Christophe Roubeix; David Godefroy; Céline Mias; Anaïs Sapienza; Luisa Riancho; Julie Degardin; Valérie Fradot; Ivana Ivkovic; Serge Picaud; Florian Sennlaub; Alexandre Denoyer; William Rostene; José Alain Sahel; Stéphane Melik Parsadaniantz; Françoise Brignole-Baudouin; Christophe Baudouin
Journal:  Stem Cell Res Ther       Date:  2015-09-16       Impact factor: 6.832

6.  Human umbilical cord blood mononuclear cells and chorionic plate-derived mesenchymal stem cells promote axon survival in a rat model of optic nerve crush injury.

Authors:  Sokjoong Chung; Seungsoo Rho; Gijin Kim; So-Ra Kim; Kwang-Hyun Baek; Myungseo Kang; Helen Lew
Journal:  Int J Mol Med       Date:  2016-03-17       Impact factor: 4.101

Review 7.  Cell Replacement Therapy for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges.

Authors:  Rosa M Coco-Martin; Salvador Pastor-Idoate; Jose Carlos Pastor
Journal:  Pharmaceutics       Date:  2021-06-11       Impact factor: 6.321

8.  Human umbilical cord blood stem cells and brain-derived neurotrophic factor for optic nerve injury: a biomechanical evaluation.

Authors:  Zhong-Jun Zhang; Ya-Jun Li; Xiao-Guang Liu; Feng-Xiao Huang; Tie-Jun Liu; Dong-Mei Jiang; Xue-Man Lv; Min Luo
Journal:  Neural Regen Res       Date:  2015-07       Impact factor: 5.135

9.  Human umbilical cord blood-derived stem cells and brain-derived neurotrophic factor protect injured optic nerve: viscoelasticity characterization.

Authors:  Xue-Man Lv; Yan Liu; Fei Wu; Yi Yuan; Min Luo
Journal:  Neural Regen Res       Date:  2016-04       Impact factor: 5.135

Review 10.  Bone Marrow-Derived Cells as a Therapeutic Approach to Optic Nerve Diseases.

Authors:  Louise A Mesentier-Louro; Camila Zaverucha-do-Valle; Paulo H Rosado-de-Castro; Almir J Silva-Junior; Pedro M Pimentel-Coelho; Rosalia Mendez-Otero; Marcelo F Santiago
Journal:  Stem Cells Int       Date:  2015-11-16       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.